Pharmakocinetics of landiolol in patients with peripheral arterial disease

Pharmakocinetics of landiolol in patients with peripheral arterial disease - Pharmakocinetics of landiolol in patients with peripheral arterial disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015077

Enrollment

Registered

2014-09-12

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral arterial disease

Interventions

Landiolol was administered at target concentrations of 0.5 and 1.0 mcg/mL for each 30 min at each target concentration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with body weight of less than 80 kg and ASA physical status 2 or 3

Exclusion criteria

Exclusion criteria: Patients with arrhythmia and patients medicated with alpha-methyldopa, clonidine or beta-blocker

Design outcomes

Primary

Measure	Time frame
Plasma concentration of landiolol from the start of administration until 20 min after the end of administration	—

Countries

Japan

Contacts

Public ContactTakayuki Kunisawa

Asahikawa Medical University Anesthesiology and CCM

taka.kunisawa@nifty.ne.jp81-166-68-2583

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026